Abuse Liability of Suboxone Versus Subutex

Phase 3 Completed 19 enrolled New York State Psychiatric Institute Schering-Plough · collab

RandomizedCrossoverDouble-blindBasic science

Summary

The study is designed to compare the abuse liabilities of intravenous buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine. We hypothesize that the abuse liability of buprenorphine/naloxone is lower than that of buprenorphine alone.

Timeline

Start: 2007-09
Primary completion: 2008-08
Completion: 2008-08

Publications

Results Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010 Apr;105(4):709-18. doi: 10.1111/j.1360-0443.2009.02843.x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Buprenorphine	Other / unclassified	4 mg	Intravenous
Subject	Buprenorphine	Other / unclassified	8 mg	Intravenous
Subject	Buprenorphine	Other / unclassified	16 mg	Intravenous
Comparator	Diacetylmorphine	Small molecule	25 mg	Intravenous
Comparator	Naloxone	Small molecule	0.4 mg	Intravenous
Comparator	Naloxone	Small molecule	1 mg	Intravenous
Comparator	Naloxone	Small molecule	2 mg	Intravenous
Comparator	Naloxone	Small molecule	4 mg	Intravenous

Abuse Liability of Suboxone Versus Subutex

Summary

Timeline

Publications

Drugs

Indications